Universal Beteiligungs und Servicegesellschaft mbH Sells 164,709 Shares of Hologic, Inc. $HOLX

Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 36.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 284,181 shares of the medical equipment provider’s stock after selling 164,709 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Hologic were worth $18,517,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. Geode Capital Management LLC boosted its stake in shares of Hologic by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after purchasing an additional 97,142 shares during the period. Invesco Ltd. raised its position in Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after purchasing an additional 764,573 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Hologic by 1.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after purchasing an additional 69,878 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock valued at $216,973,000 after buying an additional 29,133 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Hologic by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider’s stock valued at $175,331,000 after buying an additional 213,366 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In related news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is currently owned by company insiders.

Hologic Stock Performance

Shares of Hologic stock opened at $74.11 on Wednesday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock’s fifty day moving average price is $70.06 and its 200-day moving average price is $66.04. The firm has a market cap of $16.48 billion, a P/E ratio of 30.75, a P/E/G ratio of 2.54 and a beta of 0.65. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $80.31.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.01 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HOLX. Leerink Partners raised their price target on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. BTIG Research restated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Argus raised their price target on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Finally, Morgan Stanley boosted their price objective on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $79.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.